PR Newswire | October 12, 2023
Syzygy Plasmonics announced today that it has reached a strategic investment agreement with Mitsubishi Heavy Industries, Ltd. (MHI), executed through Mitsubishi Heavy Industries America, Inc. (MHIA). The agreement formalizes ties between Syzygy and MHIA, giving the global multinational engineering and manufacturing technology company greater insight into Syzygy's strategic priorities and an opportunity to support Syzygy's business execution plans.
"MHIA has been making moves to establish themselves as one of the leaders in the energy transition," said Syzygy Chief Executive Officer Trevor Best. "Formalizing our relationship with them shows their commitment to helping scale cutting edge technology and opens up new avenues for Syzygy and MHIA to work together as we commercialize our industrial decarbonization platform."
Syzygy Plasmonics is a deep-decarbonization company. It builds reactors that use light instead of heat to electrify chemical manufacturing and power a cleaner, safer world. Utilizing technology licensed from Rice University and advanced engineering, Syzygy is commercializing a universal photocatalytic reactor platform. When powered with renewable electricity, this tunable technology is designed to reduce both cost and emissions from many different chemical reactions. Starting with solutions designed to consume greenhouse gases and produce low- and zero-emissions hydrogen, the company's mission is to create a world where chemicals, fuels, and fertilizer are low cost, carbon neutral, and accessible to everyone.
Mitsubishi Heavy Industries Group
Mitsubishi Heavy Industries Group is committed to building a business that contributes to realizing a decarbonized society while investing in and collaborating with various partners with innovative technologies. This investment will help Syzygy Plasmonics to accelerate commercialization and continue its development of innovative alternative technologies, particularly those that contribute to the hydrogen ecosystem and CO2 ecosystem. Going forward, MHI will continue to enhance and diversify its solutions portfolio, providing its customers with alternative decarbonization technologies to reach their net zero goals.
PR Newswire | October 25, 2023
LBB Specialties (LBBS), a leader in specialty chemicals and ingredients distribution in North America, announces a new partnership with Viscofan DE, a global leader in collagen manufacturing. LBB Specialties will be Viscofan's preferred partner in the United States for their portfolio of premium collagen hydrolysates, including COLLinstant® and COLLinstant LMW®.
"Viscofan has over 90 years of experience in the collagen market. We are excited to bring this expertise to our customer base, as these products meet global consumer demand for highly bioavailable ingredients with a major advantage over traditional collagen formulas," said Mike DeGennaro, Senior Vice President of LBB Specialties Food & Nutrition.
Viscofan DE is the center of excellence for collagen products within the Viscofan group. Viscofan applies proprietary technologies and standardized extraction methods to process collagen from bovine skin for the development and industrial-scale production of novel collagen ingredients and biometrics.
"LBB Specialties' technical expertise and dedicated commercial team is uniquely positioned to expand our innovative offerings in the US nutraceutical market," said James Murray, Business Manager at Viscofan. "Their existing portfolio of high-quality ingredients for health and wellness applications is the perfect complement to our COLLinstant® product line of collagen peptide alternatives."
About LBB Specialties
LBB Specialties is a leader in North American specialty chemicals and ingredients. It is a diversified supplier serving end-markets including care, food & nutrition, industrial specialties, and life sciences. LBB Specialties generates approximately $500 million in revenue annually and employs more than 110 commercial team members.
Business Wire | October 10, 2023
Sapio Sciences, the science-aware™ lab informatics platform, today announced the launch of the Sapio Chemistry solution, which unifies small-molecule and large-molecule discovery workflows on a single platform. Built on the same no-code platform as Sapio’s existing large-molecule discovery electronic lab notebook solution, Sapio Chemistry enables scientists to draw insights across all their organization’s discovery experiments.
See Sapio’s new Chemistry solution for yourself in this exclusive webinar on October 11, 2023 - register here.
“Many organizations are still running decades-old electronic laboratory notebooks (ELNs) and other software for capturing chemical synthesis experiments and registering small molecules,” said Kevin Cramer, president and CEO of Sapio Sciences. “Large-molecule and small-molecule discovery have traditionally been managed on disparate systems, creating artificial islands that impede scientific collaboration and decision-making. Sapio is excited to give biopharma organizations the opportunity to consolidate all their chemistry experiments on a modern, unified lab platform.”
Sapio Chemistry is designed to facilitate collaboration among chemistry teams and their colleagues in analytical core facilities and screening labs, including contract research organizations. Advanced, chemically intelligent search built into Sapio Chemistry makes up-to-date project data easily accessible to the entire team. Out-of-the-box, configurable templates simplify the capture and sharing of chemistry experiments, including the reaction, reagents, solvents, and products through to registering synthesized compounds, batches, and lots and requesting assays. Sapio Chemistry also includes advanced capabilities for sample and inventory management, leveraging the strong sample-handling features built into the Sapio platform.
Sapio Chemistry includes the latest science-aware™ functionality from Sapio, offering the first-ever lab triple-play solution of ELN, laboratory information management system (LIMS), and Jarvis scientific data cloud all in one. Science-aware means the system unifies data and works the way scientists do with built-in tools for managing, visualizing, and analyzing data to make life in the lab simple.
About Sapio Sciences
Sapio Sciences' mission is to improve life in the lab — because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware™ lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions.
Sapio serves some of the largest global and niche brands, including biopharma, CROs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies.